C94.0 Acute erythroid leukemia

Name of the Condition

• Acute erythroid leukemia
• ICD-10 Code: C94.0

Summary

Acute erythroid leukemia is a rare subtype of acute myeloid leukemia (AML) characterized by the rapid proliferation of immature red blood cell precursors (erythroblasts) in the bone marrow. This condition disrupts normal blood cell production, leading to anemia, thrombocytopenia, and neutropenia. It is classified as a high-grade malignancy with aggressive clinical behavior.

Causes

The exact cause involves genetic mutations or chromosomal abnormalities in hematopoietic stem cells, leading to uncontrolled proliferation of erythroid precursors. Contributing factors may include prior exposure to chemotherapy or radiation, genetic predispositions, or underlying myelodysplastic syndromes.

Risk Factors

• Prior exposure to chemotherapy or radiation
• History of myelodysplastic syndromes
• Certain genetic syndromes (e.g., Down syndrome)
• Advanced age
• Male gender
• Exposure to benzene or other toxic chemicals

Symptoms

• Severe fatigue or weakness
• Unexplained weight loss
• Fever or recurrent infections
• Easy bruising or bleeding
• Shortness of breath
• Pale skin (pallor)
• Enlarged liver or spleen (hepatosplenomegaly)

Diagnosis

Diagnosis involves a physical examination, followed by blood tests (complete blood count, peripheral smear) to identify abnormal erythroblasts. Bone marrow aspiration and biopsy confirm the presence of erythroid precursors, with flow cytometry and cytogenetic analysis used to assess genetic abnormalities.

Treatment Options

Treatment typically includes intensive chemotherapy regimens, such as cytarabine-based protocols, to induce remission. Stem cell transplantation may be considered for eligible patients. Supportive care, including blood transfusions and infection management, is essential during treatment.

Prognosis and Follow-Up

Prognosis is generally poor due to the aggressive nature of the disease and high relapse rates. Follow-up involves regular monitoring of blood counts, bone marrow assessments, and imaging to detect recurrence. Long-term survival depends on response to therapy and genetic risk factors.

Complications

• Severe anemia requiring transfusions
• Life-threatening infections due to neutropenia
• Bleeding disorders from thrombocytopenia
• Organ infiltration (e.g., liver, spleen)
• Treatment-related toxicities (e.g., mucositis, organ damage)

Lifestyle & Prevention

• Avoid exposure to known carcinogens (e.g., benzene)
• Maintain a balanced diet to support overall health
• Practice good hygiene to reduce infection risk
• Follow recommended cancer screening if at high risk
• Discuss genetic counseling if a hereditary syndrome is suspected

When to Seek Professional Help

Seek immediate medical attention for persistent fatigue, unexplained bleeding, fever, or signs of infection. Prompt evaluation is critical for early diagnosis and treatment initiation.

Tips for Medical Coders

Document the presence of erythroblastic proliferation in bone marrow, along with any associated cytogenetic or molecular findings, to support code assignment. Ensure differentiation from other AML subtypes and confirm the absence of prior myeloid neoplasms when applicable.